Publication Name	World Journal of Gastroenterology
Manuscript ID	976
Country	Egypt

Received	2012-10-31 05:16
Peer-Review Started	2012-10-31 09:41
To Make the First Decision	2012-12-05 10:03
Return for Revision	2012-12-06 15:38
Revised	2013-01-29 07:41
Second Decision	2013-02-06 11:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-02-06 12:20
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-04-25 14:39
Publish the Manuscript Online	2013-05-07 10:53

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Coinfection with hepatitis C virus and schistosomiasis: Fibrosis and treatment response
Manuscript Source	Invited Manuscript
All Author List	Mahasen Abdel-Rahman, Mohammad El-Sayed, Maissa El Raziky, Aisha Elsharkawy, Wafaa El-Akel, Hossam Ghoneim, Hany Khattab and Gamal Esmat
Funding Agency and Grant Number	Funding Agency Grant Number Science and Technology Development Fund 1708
Corresponding Author	Dr. Mohammad El-Sayed, Department of Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, Cairo 11562, Egypt. mohammadelsayed76@yahoo.com
Key Words	Hepatitis C virus; Schistosomiasis; Coinfection; Fibrosis; Treatment response
Core Tip	Both hepatitis C virus (HCV) and schistosomiasis are highly endemic in Egypt and coinfection is frequently encountered. The effect of such coinfection on hepatic fibrosis and response to pegylated-interferon and ribavirin therapy (PEG-IFN/RIB) remains unclear. Our study aimed to assess the impact of schistosomiasis on hepatic fibrosis and response to PEG-IFN/RIB therapy in chronic HCV Egyptian patients. Antischistosomal antibody was positive in 27.3% of 3596 chronic HCV patients. Findings suggest positive schistosomal serology has no effect on fibrosis stage but is significantly associated with failure of response to HCV treatment despite antischistosomal therapy.
Publish Date	2013-05-07 10:53
Citation	Abdel-Rahman M, El-Sayed M, El Raziky M, Elsharkawy A, El-Akel W, Ghoneim H, Khattab H, Esmat G. Coinfection with hepatitis C virus and schistosomiasis: Fibrosis and treatment response. World J Gastroenterol 2013; 19(17): 2691-2696
URL	http://www.wjgnet.com/1007-9327/full/v19/i17/2691.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i17.2691

Full Article (PDF)	WJG-19-2691.pdf
Manuscript File	976-Reveiw.docx
Answering Reviewers	976-Answering reviewers.pdf
Copyright License Agreement	976-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	976-Language certificate.pdf
Peer-review Report	976-Peer reviews.docx
Scientific Editor Work List	976-Scientific editor work list.doc